Literature DB >> 27448744

The translocator protein gene is associated with symptom severity and cerebral pain processing in fibromyalgia.

Eva Kosek1, Sofia Martinsen2, Björn Gerdle3, Kaisa Mannerkorpi4, Monika Löfgren5, Indre Bileviciute-Ljungar6, Peter Fransson7, Martin Schalling8, Martin Ingvar9, Malin Ernberg10, Karin B Jensen11.   

Abstract

The translocator protein (TSPO) is upregulated during glia activation in chronic pain patients. TSPO constitutes the rate-limiting step in neurosteroid synthesis, thus modulating synaptic transmission. Related serotonergic mechanisms influence if pro- or anti-nociceptive neurosteroids are produced. This study investigated the effects of a functional genetic polymorphism regulating the binding affinity to the TSPO, thus affecting symptom severity and cerebral pain processing in fibromyalgia patients. Gene-to-gene interactions with a functional polymorphism of the serotonin transporter gene were assessed. Fibromyalgia patients (n=126) were genotyped regarding the polymorphisms of the TSPO (rs6971) and the serotonin transporter (5-HTTLPR/rs25531). Functional magnetic resonance imaging (n=24) was used to study brain activation during individually calibrated pressure pain. Compared to mixed/low TSPO affinity binders, the high TSPO affinity binders rated more severe pain (p=0.016) and fibromyalgia symptoms (p=0.02). A significant interaction was found between the TSPO and the serotonin transporter polymorphisms regarding pain severity (p<0.0001). Functional connectivity analyses revealed that the TSPO high affinity binding group had more pronounced pain-evoked functional connectivity in the right frontoparietal network, between the dorsolateral prefrontal area and the parietal cortex. In conclusion, fibromyalgia patients with the TSPO high affinity binding genotype reported a higher pain intensity and more severe fibromyalgia symptoms compared to mixed/low affinity binders, and this was modulated by interaction with the serotonin transporter gene. To our knowledge this is the first evidence of functional genetic polymorphisms affecting pain severity in FM and our findings are in line with proposed glia-related mechanisms. Furthermore, the functional magnetic resonance findings indicated an effect of translocator protein on the affective-motivational components of pain perception.
Copyright © 2016 The Authors. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  5-HTTLPR; Fibromyalgia; Functional magnetic resonance imaging; Gene-to-gene interactions; Genetic polymorfisms; SCL6A4; Serotonin; Serotonin transporter; Translocator protein; rs6971

Mesh:

Substances:

Year:  2016        PMID: 27448744     DOI: 10.1016/j.bbi.2016.07.150

Source DB:  PubMed          Journal:  Brain Behav Immun        ISSN: 0889-1591            Impact factor:   7.217


  9 in total

1.  Chronic non-inflammatory muscle pain: central and peripheral mediators.

Authors:  Joseph Lesnak; Kathleen A Sluka
Journal:  Curr Opin Physiol       Date:  2019-06-18

Review 2.  Neurogenic inflammation in fibromyalgia.

Authors:  Geoffrey Littlejohn; Emma Guymer
Journal:  Semin Immunopathol       Date:  2018-03-19       Impact factor: 9.623

3.  Brain glial activation in fibromyalgia - A multi-site positron emission tomography investigation.

Authors:  Daniel S Albrecht; Anton Forsberg; Angelica Sandström; Courtney Bergan; Diana Kadetoff; Ekaterina Protsenko; Jon Lampa; Yvonne C Lee; Caroline Olgart Höglund; Ciprian Catana; Simon Cervenka; Oluwaseun Akeju; Mats Lekander; George Cohen; Christer Halldin; Norman Taylor; Minhae Kim; Jacob M Hooker; Robert R Edwards; Vitaly Napadow; Eva Kosek; Marco L Loggia
Journal:  Brain Behav Immun       Date:  2018-09-14       Impact factor: 7.217

4.  Expression of mitochondrial TSPO and FAM173B is associated with inflammation and symptoms in patients with painful knee osteoarthritis.

Authors:  Vinko Palada; Aisha Siddiqah Ahmed; Anders Hugo; Maja R Radojčić; Camilla I Svensson; Eva Kosek
Journal:  Rheumatology (Oxford)       Date:  2021-04-06       Impact factor: 7.580

Review 5.  Systematic Review of the Use of Intravenous Ketamine for Fibromyalgia.

Authors:  Mila Pastrak; Alaa Abd-Elsayed; Frederick Ma; Bruce Vrooman; Ognjen Visnjevac
Journal:  Ochsner J       Date:  2021

Review 6.  Translocator Protein 18 kDa (TSPO) as a Novel Therapeutic Target for Chronic Pain.

Authors:  Jie Liu; Jingyao Huang; Zhenjiang Zhang; Rui Zhang; Zhihao Zhang; Yongxin Liu; Baoyu Ma
Journal:  Neural Plast       Date:  2022-08-29       Impact factor: 3.144

7.  Ambroxol for the treatment of fibromyalgia: science or fiction?

Authors:  Kai-Uwe Kern; Myriam Schwickert
Journal:  J Pain Res       Date:  2017-08-16       Impact factor: 3.133

8.  Effects of genetic variants in the TSPO gene on protein structure and stability.

Authors:  Vladimir M Milenkovic; Stefanie Bader; Daniel Sudria-Lopez; Ramona Siebert; Caroline Brandl; Caroline Nothdurfter; Bernhard H F Weber; Rainer Rupprecht; Christian H Wetzel
Journal:  PLoS One       Date:  2018-04-11       Impact factor: 3.240

9.  Fascial preadipocytes: another missing piece of the puzzle to understand fibromyalgia?

Authors:  Bruno Bordoni; Fabiola Marelli; Bruno Morabito; Francesca Cavallaro; David Lintonbon
Journal:  Open Access Rheumatol       Date:  2018-05-01
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.